Cited by 94Chemotherapy-induced cardiotoxicity and mitigationCell death mechanisms and regulationSphingolipid Metabolism and Signaling

Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes

Delpy, E·1999·Cardiovascular Research

Abstract

OBJECTIVES: Anthracyclines cause apoptotic death in many cell types through activation of the ceramide pathway. We tested the hypothesis that doxorubicin induces cardiac myocyte apoptosis through ceramide generation. METHODS: Adult rat ventricular myocytes were grown in the presence of 10% fetal calf serum, and exposed to 0.5 microM doxorubicin (Dox) for 1 h on the day of cell isolation (day 0). We used the membrane-permeant ceramide analog C2-ceramide (C2-cer) to mimic the effects of endogenous ceramide and PDMP to induce endogenous ceramide accumulation. Apoptosis was assessed upon morphological criteria and DNA fragmentation by the TUNEL method and agarose gel electrophoresis. Ceramide concentration was assessed using the DAG kinase assay. RESULTS: Myocyte exposure to Dox was associated with cellular and nuclear alterations typical of apoptosis on day 7 but not on day 3. At day 7, the percentage of TUNEL-positive myocytes was markedly increased in Dox-treated cultures compared to control (Cl) cultures (82 +/- 3 vs. 12 +/- 1%, n = 7; p < 0.001); internucleosomal DNA fragmentation was confirmed by the observation of DNA ladders. These alterations were associated with an increase in the intracellular ceramide concentration (1715 +/- 243 vs. 785 +/- 99 pmol/mg prot, n = 5; p < 0.01), a phenomenon also detected on day 3 (731 +/- 59 vs. 259 +/- 37 pmol/mg prot, n = 5; p < 0.001). Incubation of myocytes at day 0 with 50 microM C2-cer induced rapid cell shrinkage and DNA fragmentation (45 +/- 3 vs. 10 +/- 1% TUNEL-positive myocytes on day 1 in C2-cer-treated and Cl cultures, respectively; n = 6, p < 0.001). Myocyte exposure to 10 microM PDMP for 7 days (n = 5), caused ceramide accumulation (1.7-fold increase vs. Cl, p < 0.01), and a marked increase in the percentage of TUNEL-positive myocytes (62 +/- 6 vs. 11 +/- 3% in Cl cultures, p < 0.001). Ventricles of rats injected intraperitoneally with a cumulative dose of 14 mg/kg Dox over a period of 2 weeks also showed an increased ceramide concentration 2 weeks later (11.01 +/- 0.64 vs. 5.24 +/- 0.88 pmol/mg prot, n = 6; p < 0.001). CONCLUSION: Our study confirms the existence of a functional ceramide pathway related to apoptosis in cardiac myocytes, and points to its possible involvement in doxorubicin-induced cardiomyopathy.

Integrity signals

Registry

Crossref · 10.1016/s0008-6363(99)00142-x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased concentrations of ceramide may mediate apoptosis in the heart in response to ischemia or drugs or cytokines that promote apoptosis.

    “Although there is much evidence that increased concentrations of ceramide may mediate apoptosis in the heart in response to ischemia or drugs or cytokines that promote apoptosis, will promote cytochrome c release and apoptosis when directly applied to cardiomyocytes, and that inhibition of de novo ceramide synthesis prevents palmitate-induced apoptosis in L6 myotubes (75, 82, 276, 355, 368), it”

    From Cardiac remodeling in obesity (2008) · cites this paper as [75]

  • Ceramide promotes cytochrome c release and apoptosis when directly applied to cardiomyocytes.

    “Although there is much evidence that increased concentrations of ceramide may mediate apoptosis in the heart in response to ischemia or drugs or cytokines that promote apoptosis, will promote cytochrome c release and apoptosis when directly applied to cardiomyocytes, and that inhibition of de novo ceramide synthesis prevents palmitate-induced apoptosis in L6 myotubes (75, 82, 276, 355, 368), it”

    From Cardiac remodeling in obesity (2008) · cites this paper as [75]

  • Inhibition of de novo ceramide synthesis prevents palmitate-induced apoptosis in L6 myotubes.

    “Although there is much evidence that increased concentrations of ceramide may mediate apoptosis in the heart in response to ischemia or drugs or cytokines that promote apoptosis, will promote cytochrome c release and apoptosis when directly applied to cardiomyocytes, and that inhibition of de novo ceramide synthesis prevents palmitate-induced apoptosis in L6 myotubes (75, 82, 276, 355, 368), it”

    From Cardiac remodeling in obesity (2008) · cites this paper as [75]

The citation lists haven’t been fetched yet

References 41 · Cited by 94

Authors
Delpy, E.
Affiliations
Inserm (FR)
Corresponding author
Delpy, E
Venue
Cardiovascular Research
Published
1999-08-01
Volume
43
Issue
2
Pages
398-407
ISSN
0008-6363 (ISSN-L)
OpenAlex
W2053547821
Cited by
94
References
41
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 4 · 2012: 4
FWCI
2.91
Type
journal article
Language
en
Open access
closed
Locations
  • Cardiovascular Research (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords
doxorubicin, anthracycline cardiotoxicity, ceramide accumulation, late apoptosis, ventricular myocytes, C2-ceramide, prescription drug monitoring programs, DNA fragmentation, ceramide pathway, cardiomyocyte apoptosis, DNA ladder, TUNEL
MeSH terms
Animals, Antibiotics, Antineoplastic, Cells, Cultured, Ceramides, Doxorubicin, Enzyme Inhibitors, Male, Morpholines, Cardiomyopathies, Myocardium, Time Factors, Rats, Wistar, Apoptosis, In Situ Nick-End Labeling, Rats, DNA Fragmentation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review